Munich, Germany

F Ulrich Hartl


Average Co-Inventor Count = 6.0

ph-index = 5

Forward Citations = 58(Granted Patents)


Location History:

  • Munich, DE (2001 - 2004)
  • Kottgeisering, DE (2009)

Company Filing History:


Years Active: 2001-2009

Loading Chart...
6 patents (USPTO):

Title: **F Ulrich Hartl: Pioneering Advances in Immunotherapy**

Introduction

F Ulrich Hartl, an influential inventor based in Munich, Germany, has made significant contributions to the field of immunotherapy through his research and inventions. With a total of six patents to his name, Hartl has focused on developing innovative solutions that harness the power of heat shock proteins for treating infectious diseases and cancers.

Latest Patents

Among his latest patents are two key inventions related to heat shock protein-based vaccines and immunotherapies. The first patent involves methods and compositions aimed at inducing an immune response in a subject by administering an effective amount of at least one heat shock protein in combination with one or more defined target antigens. This approach has potential applications in treating infectious diseases and various types of cancer. The second patent similarly focuses on inducing immune responses but utilizes a heat shock protein complexed to a hybrid antigen, comprising an antigenic domain and a heat shock protein-binding domain. This innovation further underscores Hartl's commitment to advancing treatment options for serious health conditions.

Career Highlights

F Ulrich Hartl is currently affiliated with the Sloan Kettering Institute for Cancer Research, a prestigious institution known for its groundbreaking cancer research and treatment strategies. His work has garnered attention within scientific communities, elevating the understanding of heat shock proteins in therapeutic contexts.

Collaborations

Throughout his career, Hartl has collaborated with prominent scientists and researchers, including James Edward Rothman and Mee H Hoe. These partnerships have emphasized the importance of teamwork and shared knowledge in driving forward scientific innovation.

Conclusion

F Ulrich Hartl continues to be a beacon of innovation in the field of immunotherapy. His work with heat shock proteins provides promising avenues for new treatments against infectious diseases and cancers. As research progresses, Hartl's contributions will undoubtedly leave a lasting impact on the scientific community and the lives of many patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…